<DOC>
	<DOCNO>NCT00627640</DOCNO>
	<brief_summary>Parkinson 's Disease major neurodegenerative disorder progressive loss dopamine-containing neuron . The understanding PD syndrome dopamine ( DA ) deficiency lead introduction clinical practice L-dopa , precursor DA cross blood brain barrier , also use selective inhibitor MAO-B , major DA metabolising enzyme man . Safinamide inhibitor MAO-B . This phase III trial evaluate efficacy safety safinamide ( 50 100 mg p.o . q.a.m . ) compare placebo add-on therapy stable dose levodopa subject advance idiopathic Parkinson 's Disease . The principal efficacy measure increase mean daily `` '' time 18-hr diary recording period .</brief_summary>
	<brief_title>Safinamide Idiopathic Parkinson 's Disease ( IPD ) With Motor Fluctuations , add-on Levodopa</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Male female age 30 80 year diagnosis idiopathic Parkinson 's Disease 5 year duration , Hoehn Yahr stage IIV `` '' phase . Be levodoparesponsive receive treatment stable dose levodopa least 4 week . Have motor fluctuation , &gt; 1.5 hour `` '' time day . Be able maintain accurate complete diary ( 18hour ) Patients medical condition and/or take concomitant medication would put risk , interfere study evaluation , make unable complete requirement study ; . Be late stage Parkinson 's Disease , experience severe , disable peakdose biphasic dyskinesia and/or unpredictable widely swing fluctuation symptom . Current diagnosis substance abuse history alcohol drug abuse past 3 month . Have receive treatment safinamide previously . History , current depression psychosis ( e.g . schizophrenia psychotic depression ) Evidence dementia cognitive dysfunction . History allergic response anticonvulsant , levodopa , antiParkinsonian agent . Hypersensitivity contraindication MAOB inhibitor . Ophthalmologic history include follow condition : albino subject , family history hereditary retinal disease , progressive and/or severe diminution visual acuity ( i.e. , 20/70 ) , retinitis pigmentosa , retinal pigmentation due cause , active retinopathy ocular inflammation ( uveitis ) , diabetic retinopathy .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>